All Updates

All Updates

icon
Filter
Funding
Artiva Biotherapeutics to raise USD 100 million in initial public offering
Cell & Gene Therapy
Jun 28, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Jun 28, 2024

Artiva Biotherapeutics to raise USD 100 million in initial public offering

Funding

  • Natural killer-based cell therapy developer Artiva Biotherapeutics has announced an IPO to raise to USD 100 million. This comes after an earlier IPO attempt in 2021 that was withdrawn in 2022. The company will start trading on the Nasdaq under the symbol "ARTV."

  • Although the specific use of the funds was undisclosed, the company is currently conducting Phase I/Ib trials for its lead candidate, AlloNK, for autoimmune diseases such as lupus nephritis and expects to reveal the initial data of the trials in 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.